Precision health, Corporate, Community

Video: Increasing genomic capability in the United Arab Emirates

Dubai welcomes Illumina’s fifteenth Solutions Center

Increasing genomic capability in the United Arab Emirates
18 November 2022

Emirati scientists, clinicians, and dignitaries attended the opening of the Illumina Solutions Center in Dubai on November 8. The new state-of-the-art facility will expand genomics capabilities and build local expertise in genomics to advance and deliver precision medicine to patients at scale.

“We opened our UAE-based Solutions Center because we see tremendous opportunity to deepen our already-strong relationships with the country’s health and technology ministries, as well as with science and health care professionals in the region,” says Susan Tousi, chief commercial officer of Illumina. “In the era of the genome, the center will enable our partners to drive scientific discovery geared towards the Arab population, and set new standards of health care excellence at the local and regional level.”

The over 9100-square-foot Solutions Center features a fully operational laboratory housing Illumina’s latest next-generation sequencing and array technologies. The equipment can be used for a variety of clinical applications, such as oncology, genetic disease testing, noninvasive prenatal testing, and rapid diagnostic testing.

Staffed with field applications and service engineers to support Illumina’s growing number of channel partners in the region, the facility will provide training and education through guided, interactive demonstrations tailored for all experience levels.

The opening of the Solutions Center is a culmination of Illumina’s commitment to create a lasting partnership with the UAE and its scientific and health care communities.

Recent Articles

Independent testing proves DRAGEN provides a vastly more comprehensive genome
Independent testing proves DRAGEN provides a vastly more comprehensive genome
When CGP uncovers potential hereditary cancer risk
When CGP uncovers potential hereditary cancer risk
Early access users rave about Illumina’s new MiSeq i100 Series
Early access users rave about Illumina’s new MiSeq i100 Series